OPKO Health, Inc. (OPKO) is a multi-national biopharmaceutical and diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, laboratory developed tests (LTDs), point-of-care tests and pharmaceuticals and vaccines. The Company operates in two segments: pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments: pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and the pharmaceutical operations it acquired in Chile, Mexico, Israel, and Spain through acquisitions in those countries. On March 12, 2013, it completed the sale to RXi Pharmaceuticals Corporation (RXi). On March 4, 2013, it acquired Cytochroma Inc. In January 2014, the Company announced that it has completed the acquisition of Laboratorio Arama de Uruguay Limitada.